Östrogenrezeptor (ER)

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

ID	`BIO-ESTROGEN-RECEPTOR`
Art	Biomarker
Aliase	ÖstrogenrezeptorЕстрогеновий рецептор (ЕР)
Status	pending_clinical_signoff
Erkrankungen	`DIS-BREAST`
Quellen	None declared

Biomarker-Fakten

Biomarker-Typ	protein_expression_ihc
Messung	VerfahrenImmunhistochemie auf FFPE-Tumorgewebe (ASCO/CAP-validierter Antikörper) EinheitenProzent der Tumorkerne Färbung Typischer Bereich 0 100
Verwandte Biomarker	`BIO-PROGESTERONE-RECEPTOR` `BIO-HER2-SOLID`

Anmerkungen

Fundamentaler Biomarker für die Zuordnung von Brustkrebs-Subtypen. Antriebskraft für die Zulassung zur endokrinen Therapie und CDK4/6i-Indikation. Kreuzvalidiert mit PR für die HR-positive Klassifizierung.

Verwendet von

Biomarker

BIO-ESR1 - ESR1-Mutation (Ligan-bindende Domäne)
BIO-HER2-LOW - HER2-niedrig (Brust — IHC 1+ ODER IHC 2+ ISH-negativ)
BIO-HER2-ULTRALOW - HER2-ultralow (Brust — IHC > 0 < 1+; schwache/unvollständige Membranfärbung ≤ 10 %)
BIO-PIK3CA-H1047R - PIK3CA H1047R Mutation
BIO-PROGESTERONE-RECEPTOR - Progesteronrezeptor (PR)

Kapitel des Handbuchs

HB-BREAST-HER2-POS-MET-1L - HER2+ metastasierter Brustkrebs:
HB-BREAST-HR-POS-HER2-NEG-1L - HR+/HER2- metastasierter Brustkrebs:

Handbuchfragen

HQ-BREAST-HER2-POS-1L-003 - HQ-BREAST-HER2-POS-1L-003

Anwendungsgebiet

IND-BREAST-BRCA-MET-TALAZOPARIB - IND-BREAST-BRCA-MET-TALAZOPARIB
IND-BREAST-HER2-LOW-2L-DATO-DXD - IND-BREAST-HER2-LOW-2L-DATO-DXD
IND-BREAST-HR-POS-1L-INAVOLISIB - IND-BREAST-HR-POS-1L-INAVOLISIB
IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB - IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB
IND-BREAST-HR-POS-2L-DATO-DXD - IND-BREAST-HR-POS-2L-DATO-DXD
IND-BREAST-HR-POS-2L-ESR1-ELACESTRANT - IND-BREAST-HR-POS-2L-ESR1-ELACESTRANT
IND-BREAST-HR-POS-2L-FUL-EVEROLIMUS - IND-BREAST-HR-POS-2L-FUL-EVEROLIMUS
IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB - IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB
IND-BREAST-HR-POS-2L-T-DXD-HER2-LOW - IND-BREAST-HR-POS-2L-T-DXD-HER2-LOW
IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT - IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT
IND-BREAST-HR-POS-EARLY-ADJ-CDK46I - IND-BREAST-HR-POS-EARLY-ADJ-CDK46I
IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB - IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB
IND-BREAST-HR-POS-MAINT-CDK46I - IND-BREAST-HR-POS-MAINT-CDK46I
IND-BREAST-HR-POS-MET-1L-CDKI - IND-BREAST-HR-POS-MET-1L-CDKI
IND-BREAST-TNBC-2L-BRCA-OLAPARIB - IND-BREAST-TNBC-2L-BRCA-OLAPARIB
IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB - IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB
IND-BREAST-TNBC-2L-DATO-DXD - IND-BREAST-TNBC-2L-DATO-DXD
IND-BREAST-TNBC-2L-SACITUZUMAB - IND-BREAST-TNBC-2L-SACITUZUMAB
IND-BREAST-TNBC-2L-T-DXD-HER2-LOW - IND-BREAST-TNBC-2L-T-DXD-HER2-LOW
IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD - IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD
IND-BREAST-TNBC-EARLY-NEOADJUVANT - IND-BREAST-TNBC-EARLY-NEOADJUVANT

Fragebogen

QUEST-BREAST-1L-STUB - Invasiver Brustkrebs — erste Zeile

Warnhinweis

RF-BREAST-TNBC - Triple-negative Brustkrebs (TNBC): Östrogenrezeptor (ER) < 1 % nukleare Färbung auf IHC...

Prüfungen

TEST-ER-PR-IHC - ER + PR Immunhistochemie am Tumor